This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Herb Greenberg

Editor, Herb Greenberg's Reality Check

Herb Greenberg is the editor of Herb Greenberg's Reality Check, a subscription newsletter designed to help investors better manage risk. He writes a daily blog for TheStreet's main free Web site and contributes to its Real Money's "Columnist Conversation" column as well as being a regular contributor for CNBC.

Greenberg has been a financial journalist for more than 30 years, working most recently as a senior stocks commentator on CNBC's business day programming and on He was also co-president of Greenberg Meritz Research & Analytics. He is a former weekend investor columnist for The Wall Street Journal and a former senior columnist for MarketWatch.

Prior to joining MarketWatch, Greenberg was senior columnist for TheStreet. He previously spent 10 years as the "Business Insider" columnist for the San Francisco Chronicle and nearly seven years as Fortune magazine's monthly "Against the Grain" columnist. Before that, he was the New York financial correspondent for the Chicago Tribune and a financial reporter in its Chicago newsroom. Greenberg has held various positions at other media outlets including Crain's Chicago Business and the St. Paul Pioneer Press.

Greenberg holds a bachelor's degree in journalism from the University of Miami.

Herb Greenberg
By This Author:
Page 2 of 473

Greenberg: CBI's 'The Shorts are Conflicted' Strategy

By Herb Greenberg

Disclosure: I've done zero work, and have no intentions to do any work, on Chicago Bridge & Iron CBI, which was the focus of an accounting takedown by Prescience Point Research Group.But I do have a take on CBI's response -- and I wouldn't be saying anything if it wasn't for the nature of its response.Not this part:CB&I has reviewed the report and strongly disagrees with its assumptions and conclusions.But this part:Notably, the report warns readers to assume that the short-selling firm and/or its affiliates hold short positions in CB&I common stock and that they stand to realize significant gains in the event that CB&I's stock price declines. CB&I believes that this conflict of interest should cause the report and its conclusions to be viewed skeptically.To which I say: Of course they're conflicted -- but no more or less conflicted than somebody own owns the stock. Prescience Point, which says it spoke with the company twice during its research, discloses that it's short at the top of its report.This ridiculous concept of trying to deflect critical commentary because the author is short is feeble, amateurish and, well, absurd, unless the company also criticizes bullish reports by analysts who it believes are conflicted because they own the stock.Reality: Everybody, if they own or short a stock, is conflicted. Everybody talks their book. That's Wall Street.

02:01PM 06/18/14

Greenberg: The Tesla-izing of SolarCity?

By Herb Greenberg

If all else fails, or at least the stock isn't sizzling the way it should be, change the story. That's the moral of SolarCity, with news that it's planning to acquire Silevo, an unknown maker of high-efficient solar panels. The deal, in SolarCity's words, will make it the "most vertically integrated solar company in the world." We can slice it and dice it any way we want, but to Reality Check the most striking part of the the deal was the role Elon Musk, SolarCity's chairman: He opened the call and pretty much ended it. Until now, he has has been much more of a silent partner at a company run by his cousins, Lyndon and Peter Rive. The obvious question: Why do this deal?

05:31PM 06/17/14


Quick Hit: The Tesla-izing of SolarCity? (Reality Check $)

By Herb Greenberg

News that SolarCity is getting into the manufacturing business has certainly goosed its stock, as the company gets renewed "story stock"ÿ status, with the added bonus of the Elon Musk afterglow.

03:09PM 06/17/14


Quick Hit: Why Nuance Is Staying on the Watch List (Reality Check $)

By Herb Greenberg

The deal chatter surrounding the company appears to be signaling just how bad its underlying performance really is.

02:27PM 06/16/14


Notes From Herb: TIBX, BDBD, VRX, TWTR (Reality Check $)

By Herb Greenberg

Here is the latest roundup of Reality Check and the Watch List.

05:43AM 06/16/14

Greenberg: Valeant Claims Critics Use ‘Wrong Assumptions’

By Herb Greenberg

In a letter to employees filed with the SEC Thursday, Valeant Pharmaceuticals' CEO Michael Pearson claimed critics are using “the wrong assumptions” as they analyze the company.Wrong assumptions. Really? That’s like a company telling a reporter or analyst, who pushes too hard, that they’re asking the “wrong” questions. (Which, in general, usually means they're the right questions.)From the letter:"Our actions have generated a lot of attention from the media, and we expect this transaction will continue to be the focus of many press reports. Unfortunately, some of these reports have criticized our overall business model and raised questions about our approach to R&D. We disagree with these criticisms and they are often based upon wrong assumptions, and we have been setting the record straight with facts about our operating model and the performance of our businesses."

07:42AM 06/13/14

Greenberg: Science May Not Support Boulder Brands' Gluten Claims

By Herb Greenberg

I totally missed this story when it first came out in May, but it's just as relevant today -- even more so with the surge in shares of Boulder Brands BDBD, a gluten-free play: The doctor behind the gluten-free craze says he was wrong.Dr. Peter Gibson's reversal has been widely reported in a variety of publications, including Real Clear Science, the New Yorker and even on Good Morning America.But you wouldn't know it by the stock-goosing comments of Boulder Brands' CEO Stephen Hughes, at a William Blair conference earlier this week. Boulder owns a number of leading gluten-free brands, including Udi's and Glutino.In his presentation, speaking of gluten, he said:"So the reality is, this is one of those ingredients that we screwed around with. We hybridized wheat to make it more glutinous, so you could make bread faster, cheaper, better. Gluten is glue in Latin, and what we created was something that did make better bread, did make cheaper bread, but it's very hard to digest and it creates a lot of unintended consequences."

02:09PM 06/12/14


New Green Flag: Tibco Is Ripe for Activist Action (Updated) (Reality Check $)

By Herb Greenberg

Tibco Software has quietly attracted value-oriented investors known to rattle cages.

07:48AM 06/12/14


Ulta's Beauty May Only Be Skin-Deep (Reality Check $)

By Herb Greenberg

That lovely comps growth came at the expense of gross margin. Plus, updates on Neustar and RealPage.

07:38AM 06/11/14

Greenberg: United 'One Sick Bird'

By Herb Greenberg

The "One Sick Bird" in that headline, regarding United Continental Holdings, is straight out of a headline in today's Wall Street Journal, which refers to the airline as "one sick bird."I fly United monthly from San Diego to New York. I have Gold status. I generally sit in first class, which means I should see the airline at its best.What I see is an airline that offers zero consistency in product, morale or service.And this is four years after the two airlines merged. Yet, as the Journal points out, they still haven't merged their fleets because they can't get the flight attendants to sign a new, joint contract. (Compare that with Delta, which somehow not only managed to rapidly merge two airlines, but do it swiftly and almost seamlessly.)In the Journal piece, United CEO Jeff Smisek, who hit my list of nominees last year for Worst CEO, put the blame everywhere but at his office. He said, notably:"Every hub has to earn its keep every day. Nothing is sacrosanct at any hub. We will make adjustments as are appropriate."

10:46AM 06/09/14

Page 2 of 473

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,078.22 +134.41 0.79%
S&P 500 1,978.28 +10.71 0.54%
NASDAQ 4,445.4260 +29.9360 0.68%

Brokerage Partners

Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs